About Mersana Therapeutics, Inc. - Common Stock (MRSN)
Mersana Therapeutics is a biotechnology company focused on the development of innovative treatments for cancer. The company specializes in advancing antibody-drug conjugates (ADCs), which are targeted therapies designed to deliver potent cytotoxic agents directly to cancer cells while minimizing damage to healthy tissue. Mersana is dedicated to improving patient outcomes through its proprietary technology platform, which enables the design of highly effective treatments aimed at addressing various types of tumors. With a strong emphasis on research and development, the company is committed to bringing novel therapies to market that address unmet medical needs in the oncology space. Read More
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Mersana Therapeutics, Inc. (NasdaqGS: MRSN) to Day One Biopharmaceuticals, Inc. Under the terms of the proposed transaction, shareholders of Mersana will receive $25.00 per share in cash plus one non-tradable contingent value right (CVR) per share to receive certain potential milestone payments of up to $30.25 per CVR in cash, for total consideration of up to $55.25 per share in cash. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
BALA CYNWYD, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mersana Therapeutics, Inc. (NASDAQ: MRSN) to Day One Biopharmaceuticals, Inc. is fair to Mersana shareholders. Under the terms of the proposed transaction, Mersana shareholders will receive $25.00 per share in cash plus one non-tradable contingent value right (CVR) per share to receive certain potential milestone payments of up to $30.25 per CVR in cash, for total consideration of up to $55.25 per share in cash.
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top gainers and losers in today's session.
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
